GBG
Government
Bioscience
Grants

Updated Monthly

December 11, 2024

Prepared for:

BIOUTAH

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:

G2G Consulting

Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com
@G2Gconsulting

GBG Report

Updated Monthly

December 11, 2024

https://www.g2gconsulting.com/gbg-reporting-service/

TABLE OF CONTENTS

New Opportunities

Recurring Opportunities

December 19, 2024 – Join us for G2G's Monthly Non-Dilutive Funding: GBG Reporting Service Webinar at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you're an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

January 22, 2025 – Don't miss G2G's MHSRS webinar at 12pm EST: Work with the Experts on DoD Funding for Life Science & Biotech Companies!

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (2)		
1.	Draft: ARPA-H ImagiNg Data EXchange (INDEX) (ARPA-H) ARPA-H-SN-25-113	The INDEX program aims to create a platform that seamlessly links data providers, data users, and service providers with high quality images that will enable robust, trustworthy AI tool development for pathology and radiology. The program seeks to increase the number, type, and quality of images available for ML models, as well as boost geographic, racial, and ethnic diversity of images. https://sam.gov/opp/c030e6b7512e49f59b44327267ae38c4/view https://solutions.arpa-h.gov/Events/INDEX/	Dependent upon proposal and available funds	Proposers' Day: 1/9/25 Solution Summary: 1/23/25
2.	Artificial Intelligence in Pre-clinical Drug Development for AD/ADRD (R01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AG-24-049	This NOFO invites applications that propose to apply existing or newly developed AI/ML methods to various aspects of drug discovery and preclinical drug development to accelerate the identification, optimization, and selection of preclinical drug candidates for the treatment and prevention of AD/ADRD and increase their likelihood of success during clinical drug development. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-049.html	Up to $1 million per year, for up to 5 years	Letter of intent: 1/13/25 Proposal: 2/13/25
		BIOMEDICAL RESEARCH (9)		
3.	Emerging Health Innovators (EHI) Initiative Proposers' Day (ARPA-H) ARPA-H-SN-25-119	The EHI Initiative aims to increase access to government research funding and address health care gaps in the U.S. for early career investigators and community innovators. Track 1, Technology-driven Innovation supports early career investigators in developing innovative health technologies. Track 2, Community-center Innovation empowers community innovators to develop technology that addresses specific community needs https://sam.gov/opp/8e02ff4dfca4417696608d141d882bef/view https://solutions.arpa-h.gov/Events/EHI/	Dependent upon proposal and award mechanism	Proposers' Day: 1/8/25 Estimated post date: December 2024

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
4.	Advancing Clinical Trial Readiness (ACTR) Initiative (ARPA-H) ARPA-H-SN-25-121	The ACTR Initiative aims to transform clinical trials by developing a robust, efficient, and decentralized trial infrastructure. The core focus of the effort is to create the tools, network, and infrastructure necessary for decentralized and on-demand clinical trials that would enable 90% of eligible Americans to participate in clinical trials within 30 minutes of their home. ACTR seeks proposals across three technical areas: Automatic Clinical Trial Data Prompting & Extraction; Research and Participant Identification & Engagement; and Trial-Grade Data Validation and Auditing. https://www.customerexperiencehub.org/actr/ https://solutions.arpa-h.gov/ACTR	TBD	Proposers' Day: 1/16/25
5.	NSF/CASIS Collaboration on Tissue Engineering and Mechanobiology on the International Space Station to Benefit Life on Earth (NSF/CASIS) NSF 25-513	The solicitation seeks to increase use of the ISS National Lab for flight research projects in the field of biomedical engineering. Ideal proposals will describe a commercial, civil, or academic project to achieve research or technology development objectives that will directly impact fundamental studies on cellular engineering, tissue engineering, and models of physiological systems. https://new.nsf.gov/funding/opportunities/nsfcasis-collaboration-tissue-engineering-mechanobiology/nsf25-513/solicitation	Up to $400,000, for up to 3 years	Proposal: 3/18/25
6.	Technology Development Research for Establishing Feasibility and Proof of Concept; and Focused Technology Research and Development (R21/R01 Clinical Trial Not Allowed) (NIH/NIGMS) PAR-25-202 (R21) PAR-25-203 (R01)	These NOFOs support exploratory research leading to proof of concept; and projects relevant to the NIGMS mission that focus solely on the development of technologies with potential to enable acquisition of biomedical knowledge. Project outcomes may include: laboratory instruments and other devices; algorithms and software; chemical reagents and processes; biological molecules or systems that have been modified by human intervention for use as research tools. https://grants.nih.gov/grants/guide/pa-files/PAR-25-202.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-25-203.html (R01)	Up to $275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOFOs open through 1/7/28
7.	Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed) (NIH/ORIP) PAR-25-273	This NOFO encourages innovative research to develop, improve, characterize, and preserve animal models as well as animal model related biological materials, technologies, and new approach methodologies (NAMs) for studies relevant to human health and disease. This NOFO also seeks projects aimed at improving the diagnosis and control of diseases that could confound or interfere with animal use in biomedical research. https://grants.nih.gov/grants/guide/pa-files/PAR-25-273.html	Up to $275,000, for up to 2 years	Multiple deadlines; NOFO open through 1/7/28

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
8.	Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) (NIH/NCI) PAR-25-321	This NOFO encourages submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. https://grants.nih.gov/grants/guide/pa-files/PAR-25-321.html	Up to $275,000, for up to 2 years	Multiple deadlines; NOFO open through 11/16/27
9.	Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional) (NIH Common Fund) RFA-RM-24-010	The Complement-ARIE program will accelerate the development, standardization, validation, and use of human-based New Approach Methodologies (NAMs). Complement-ARIE will significantly advance understanding of human health and disease by providing a range of mature and/or validated and standardized biomedical research models. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-010.html	Up to $2 million per year, for up to 5 years	Letter of intent: 1/28/25 Proposal: 2/28/25
10.	In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems (UG3/UH3 Clinical Trials Not Allowed (NIH Common Fund) RFA-RM-24-012	The goal of the Advancing Non-Invasive Optical Imaging Approaches for Biological Systems initiative is development of next-generation non-invasive or minimally invasive optical imaging techniques to overcome the problem of light scattering in biological systems resulting in high spatial and temporal resolution optical images at significantly greater depths within biological tissues than is currently possible. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-012.html	Dependent upon proposal, for up to 3 years	Letter of intent: 2/7/25 Proposal: 3/7/25
		BIOTECHNOLOGY AND BIOMANUFACTURING (1)		
11.	Project Call 5.0 (BioMADE)	Project Call 5.0 supports projects related to Technology and Innovation, Education and Workforce Development, and 4S (Safety, Security, Sustainability, and Social Responsibility). The Technology and Innovation call focuses on advancing bioindustrial manufacturing by developing underlying tools and technologies to support diverse applications. Focus areas are: Data acquisition for AI/ML predictive modeling; Reducing drivers of cost; Standardization of TEA guidelines. Project Call 5.0 includes the opportunity for NSF researchers to participate as part of an integrated project team. https://www.biomade.org/news/announcing-project-call-5	Up to $2 million, for up to 2 years Dependent upon proposal and award mechanism Cost-sharing required	White paper: 1/22/25 Full proposal: 4/18/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER (26)		
12.	Forecast: Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics (HHS/FDA) FOR-FD-25-015	This NOFO will support applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics. The main outcomes of this work will be publications and presentations; however, FDA staff anticipate substantial involvement in study design and reviewing interim deliverables to ensure that the studies develop practical approaches and solutions that have the potential to inform regulatory decision making in the future. https://www.grants.gov/search-results-detail/357261	TBD	TBD
13.	DOD Glioblastoma, Transformative Consortium Award (DoD/CDMRP) HT942524GBMRPTCA	The GBMRP FY24 Transformative Consortium Award (TCA) is designed to support a multidisciplinary collaborative effort of at least four, but not more than five, distinct yet complementary projects that collectively address a central hypothesis. Applications for the TCA may propose clinical or translational research projects and/or clinical trials and must address at least one of the FY24 GBMRP Areas of Emphasis. https://cdmrp.health.mil/funding/gbmrp	Up to $9.09 million, for up to 4 years	Pre-application: 12/23/24 Proposal: 1/13/25
14.	Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21/R01 Clinical Trial Not Allowed) (NIH/NCI) PA-25-173 (R21) PA-25-174 (R01)	These NOFOs solicit research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics on normal tissue, tumor cells and the tumor microenvironment. https://grants.nih.gov/grants/guide/pa-files/PA-25-173.html (R21) https://grants.nih.gov/grants/guide/pa-files/PA-25-174.html (R01)	Up to $275,000, for up to 2 years (R21) Up to $500,000, for up to 5 years (R01)	Proposal: 2/16/25 (R21) Proposal: 2/5/25 (R01)
15.	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01/R21 Clinical Trial Optional) (NIH/NCI) PA-25-294 (R01) PA-25-295 (R21)	These NOFOs support meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. https://grants.nih.gov/grants/guide/pa-files/PA-25-294.html (R01) https://grants.nih.gov/grants/guide/pa-files/PA-25-295.html (R21)	Up to $500,000 per year, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 7/16/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
16.	Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional/R21 Clinical Trial Not Allowed) (NIH/NCI) PAR-25-069 (R01) PAR-25-070 (R21)	These NOFOs invite applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/ glucose dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. https://grants.nih.gov/grants/guide/pa-files/PAR-25-069.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-070.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 11/16/26
17.	Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required) (NIH/NCI) PAR-25-072	This NOFO will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. https://grants.nih.gov/grants/guide/pa-files/PAR-25-072.html	Up to $500,000 per year, for up to 2 years (UG3) Up to $750,000 per year, for up to 4 years (UH3)	Multiple deadlines; NOFO open through 11/17/25
18.	Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis; and Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) (NIH/NCI) PAR-25-081 PAR-25-167	These NOFOs solicit research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM, related to selected NCI research programs; as well as applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. https://grants.nih.gov/grants/guide/pa-files/PAR-25-081.html https://grants.nih.gov/grants/guide/pa-files/PAR-25-167.html	Up to $499,999 per year, for up to 5 years (081) Dependent upon proposal, for up to 5 years (167)	Multiple deadlines; NOFOs open through 1/7/27
19.	Impacts of climate change across the cancer control continuum (R01/R21 Clinical Trial Optional) (NIH/NCI) PAR-25-094 (R01) PAR-25-152 (R21)	These NOFOs aim to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors. https://grants.nih.gov/grants/guide/pa-files/PAR-25-094.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-152.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 3/16/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
20.	Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01/R21 Clinical Trials Not Allowed) (NIH) PAR-25-095 (R01) PAR-25-096 (R21)	These NOFOs encourage submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. https://grants.nih.gov/grants/guide/pa-files/PAR-25-095.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-096.html (R21)	Up to $350,000 per year, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 7/16/26
21.	Biology of Bladder Cancer (R21 Clinical Trial Optional) (NIH/NCI) PAR-25-128 (R21) PAR-25-129 (R01)	These NOFOs encourage applications that investigate the biology and underlying mechanisms of bladder cancer. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. https://grants.nih.gov/grants/guide/pa-files/PAR-25-128.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-25-129.html (R01)	Up to $275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOFOs open through 7/16/25
22.	Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) (NIH/NCI) PAR-25-171	This NOFO supports the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. https://grants.nih.gov/grants/guide/pa-files/PAR-25-171.html	Up to $400,000 per year, for up to 5 years	Letter of intent: 1/5/25 Proposal: 2/5/25
23.	Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R01/R21 Clinical Trial Optional) (NIH) PAR-25-240 (R01) PAR-25-241 (R21)	These NOFOs support policy research projects that examine new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. https://grants.nih.gov/grants/guide/pa-files/PAR-25-240.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-241.html (R21)	Up to $500,000 per year, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 11/16/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
24.	Basic Research in Cancer Health Disparities (R01/R21 Clinical Trial Not Allowed) (NIH/NCI) PAR-25-243 (R01) PAR-25-244 (R21)	These NOFOs encourage grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. They will support innovative, and pilot and feasibility studies designed to investigate biological/genetic contributors of cancer health disparities. https://grants.nih.gov/grants/guide/pa-files/PAR-25-243.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-244.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 11/16/27
25.	Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) (NIH/NCI) PAR-25-248	This NOFO encourages applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. This NOFO supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. https://grants.nih.gov/grants/guide/pa-files/PAR-25-248.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 10/8/27
26.	Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) (NIH/NCI) PAR-25-254	This NOFO solicits mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. https://grants.nih.gov/grants/guide/pa-files/PAR-25-254.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 3/5/26
27.	Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) (NIH/NCI) PAR-25-275	This NOFO encourages grant applications to support research in established cancer epidemiology cohort studies. Applications must include hypothesis-based research using data from an established cohort study and are expected to include support for cohort maintenance, continued follow-up, and sharing of the existing resources in addition to addressing research questions across the cancer control continuum. https://grants.nih.gov/grants/guide/pa-files/PAR-25-275.html	Dependent upon proposal, for up to 5 years	Proposal: 2/28/25
28.	Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 – Clinical Trials Optional) (NIH/NIMHD/NIAAA/NCI) PAR-25-299	This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the U.S. https://grants.nih.gov/grants/guide/pa-files/PAR-25-299.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 7/5/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
29.	Reagent Target Requests to the NCI Antibody Characterization Program (NIH/NCI)	This program provides reagents and other critical resources to support protein/peptide measurement and analysis efforts. For more information on this program and reagents currently available go to https://proteomics.cancer.gov and https://antibodies.cancer.gov. The CPTAC Antibody Portal provides access to well characterized affinity reagents. Currently, monoclonal antibodies are being generated and characterized to proteins associated with human cancer. For each protein target, antibodies are generated and characterized using standardized assays. https://proteomics.cancer.gov/antibody-portal/how-apply	Resource support	Submission: 2/14/25
		CARDIOVASCULAR AND PULMONARY HEALTH (7)		
30.	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33/R61/R33 Clinical Trial Required) (NIH/NHLBI) PAR-25-025 (R33) PAR-25-026 (R61/33)	These NOFOs support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for HLBS disorders in adults and children. The proposed trial can be single or multi-site. https://grants.nih.gov/grants/guide/pa-files/PAR-25-025.html (R33) https://grants.nih.gov/grants/guide/pa-files/PAR-25-026.html (R61/R33)	Up to $1.515 million per year, for up to 3 years (R33) Up to $250,000 per year, for up to 2 years (R61)	Multiple deadlines; NOFOs open through 1/7/27
31.	Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) (NIH/NHLBI) RFA-HL-26-016	This NOFO solicits applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address HLBS-related disorders and diseases. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-016.html	Up to $350,000 per year, for up to 2 years	Multiple deadlines; NOFOs open through 12/23/27
32.	Catalyze: Product Definition for Small Molecules, Biologics and Combination Products (R61/R33 – Clinical Trials Not Allowed) (NIH/NHLBI) RFA-HL-26-017 (R61/R33) RFA-HL-26-018 (R33)	These NOFOs will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat HLBS diseases and disorders. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-017.html (R61/R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-018.html (R33)	Up to $400,000 per year, for up to 2 years (R61) Up to $400,000 per year, for up to 2 years (R33) Cost matching is required for the R33 awards	Multiple deadlines; NOFOs open through 12/23/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH		
33.	Catalyze Product Definition – Medical Device Prototype Optimization; and design/testing and disease target identification and assay development (R61/R33) (NIH/NHLBI) RFA-HL-26-019 (R61/R33) RFA-HL-26-020 (R33)	These NOFOs will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-019.html (R61/R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-020.html (R33)	Up to $300,000 per year, for up to 2 years (R61) Up to $300,000 per year, for up to 2 years (R33) Cost matching is required for the R33 awards	Multiple deadlines; NOFOs open through 12/23/27
		CENTRAL NERVOUS SYSTEM (3)		
34.	NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) (NIH/NINDS) PAR-25-052	This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. https://grants.nih.gov/grants/guide/pa-files/PAR-25-052.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 11/19/26
35.	BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) (NIH) RFA-EY-25-001	This NOFO seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation. https://grants.nih.gov/grants/guide/rfa-files/RFA-EY-25-001.html	Up to $400,000, for up to 3 years	Multiple deadlines; NOFO open through 6/15/26
36.	Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed) (NIH/NINDS/OD) RFA-NS-25-025	This NOFO solicits applications for support of exploratory/developmental studies aimed at accelerating progress toward understanding, preventing or treating Guillain Barre Syndrome (GBS) and/or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Innovative studies of disease mechanisms, susceptibility factors, model systems, biomarkers and treatments are encouraged. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-025.html	Up to $275,000, for up to 2 years	Multiple deadlines; NOFO open through 10/3/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CHRONIC PAIN & PAIN MANAGEMENT (1)		
37.	Managing Pain Topical PCORI Funding Announcement -- Cycle 1 2025 (PCORI)	PCORI seeks to fund studies that address meaningful decisional dilemmas faced by patients, clinicians and members of the broader health and healthcare community when seeking and obtaining pain-related care and to improve patient-centered outcomes. PCORI is particularly interested in submissions that address the following Special Areas of Emphasis (SAEs): Urogynecological and pelvic pain; Pain in individuals living with limitations in cognitive functioning; Pain in individuals living with sickle cell disease; and Neuropathic pain. https://www.pcori.org/funding-opportunities/announcement/managing-pain-topical-pcori-funding-announcement-cycle-1-2025	Up to $12 million, for up to 5 years	Letter of intent: 1/14/25 Proposal: 5/6/25
		COGNITIVE AND BRAIN HEALTH (17)		
38.	Forecast: Biomarkers of Cognitive Decline and Dementias of Aging in Individuals within the Autism Spectrum (U01 Clinical Trial Optional) (NIH/NIA) NOT-AG-24-082	This NOFO will invite applications to conduct observational studies in individuals living with Autism Spectrum Disorders (ASD) along the lifespan. The overarching goal is to use deep phenotyping, including neuroimaging, molecular and other approaches, to discover and characterize biomarkers of neurodegeneration in this population, in relation with clinical manifestation of age-related decline in multiple cognitive domains. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-082.html	Dependent upon proposal, for up to 5 years	Estimated post date: 12/15/24 Estimated proposal date: 2/15/25
39.	Forecast: Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) (NIH/NIA) NOT-AG-24-084	This NOFO will invite applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of AD/ADRD using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-084.html	TBD	Estimated post date: 12/31/24 Estimated proposal date: 3/7/25
40.	Forecast: Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) (NIH/NIA) NOT-AG-24-085	This NOFO will 1) invite applications that propose to develop and implement early- to late-stage clinical trials of promising pharmacological and non-pharmacological interventions to prevent and/or treat the cognitive, behavioral, and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD, and 2) stimulate studies to enhance trial design and methods. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-085.html	TBD	Estimated post date: 12/31/24 Estimated proposal date: 3/7/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
41.	Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional) (NIH/NIA) PA-25-246	The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. https://grants.nih.gov/grants/guide/pa-files/PA-25-246.html	Up to $100,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 3/16/26
42.	Cellular and Molecular Biology of Complex Brain Disorders (R21/R01 Clinical Trial Not Allowed) (NIH/NIMH) PAR-25-037 (R21) PAR-25-038 (R01)	These NOFO encourage research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. Studies may be either hypothesis-generating or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. https://grants.nih.gov/grants/guide/pa-files/PAR-25-037.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-25-038.html (R01)	Up to $275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOFOs open through 7/16/27
43.	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21/R01 Clinical Trial Optional) (NIH/NIMH/NIA) PAR-25-064 (R21) PAR-25-065 (R01)	These NOFOs encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with AD/ADRD. The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. https://grants.nih.gov/grants/guide/pa-files/PAR-25-064.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html (R01)	Up to $275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOFOs open through 7/16/26
44.	Analytical and Clinical Validation of Biomarkers for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional) (NIH/NIA) PAR-25-209	This NOFO invites applications to accelerate the establishment of effective and reliable biomarkers of AD/ADRD for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the FDA's Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways. https://grants.nih.gov/grants/guide/pa-files/PAR-25-209.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 3/5/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
45.	Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional) (NIH/NIA) PAR-25-224	This NOFO invites applications that apply a cross-disciplinary and team science approach to gain a comprehensive mechanistic understanding of the impact of sex differences on the molecular trajectories of brain aging on the phenotypes of risk and resilience to AD/ADRD, and on the molecular determinants underlying responsiveness to pharmacologic and non-pharmacologic interventions. https://grants.nih.gov/grants/guide/pa-files/PAR-25-224.html	Dependent upon proposal, for up to 5 years	Letter of intent: 1/21/25 Proposal: 2/21/25
46.	Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) (NIH/NIA) PAR-25-226	This NOFO encourages applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for AD/ADRD. Candidate interventions evaluated through this program must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum, from pre-symptomatic to more severe stages of disease. https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 11/19/26
47.	New Approaches for Measuring Brain Changes Across Longer Timespans (R21/R01 Clinical Trial Optional) (NIH/NIA/NICHD/NCI) PAR-25-272 (R21) PAR-25-279 (R01)	These NOFOs encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. https://grants.nih.gov/grants/guide/pa-files/PAR-25-272.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-25-279.html (R01)	Up to $275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOFOs open through 3/16/27
48.	Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) (NIH/NIA) PAR-25-297	This NOFO invites applications proposing pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. https://grants.nih.gov/grants/guide/pa-files/PAR-25-297.html	Up to $1.5 million per year, for up to 5 years	Multiple deadlines; NOFO open through 11/5/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
49.	Coordination Center for the Alzheimer's Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-25-015	This NOFO supports the Coordination Center for the ADSP Consortium. The Center will: Provide leadership and technical expertise in all aspects of ADSP research; Lead and coordinate cross-consortium functions, including effective communication, collaboration, outreach, dissemination, training, and coordination across the components of the ADSP; Be the main conduit for collaboration with NIH- and NIA-funded programs and the global research community in the genetics and genomics of AD/ADRD. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-015.html	Up to $1 million per year, for up to 5 years	Letter of intent: 1/14/25 Proposal: 2/14/25
50.	BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) (NIH) RFA-MH-26-170	The purpose of this NOFO is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-26-170.html	Dependent upon proposal, for up to 3 years	Multiple deadlines; NOFO open through 2/8/27
51.	BRAIN Initiative: Promoting Equity Through BRAIN Technology Partnerships (R34 - Clinical Trials Not Allowed) (NIH) RFA-NS-25-016	This NOFO is intended for investigators at institutions that have not previously been major recipients of NIH funding. The goal is for these investigators to adopt and integrate BRAIN Initiative resources into their line of research. Applications are limited to utilizing well-developed, well-validated resource(s) described on this list of NIH BRAIN Initiative U24 Programs or this list of BRAIN Initiative Alliance Developed Resources and Tools. https://braininitiative.nih.gov/research/dissemination/u24-program https://www.braininitiative.org/toolmakers-resources/ https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-016.html	Up to $450,000, for up to 3 years	Multiple deadlines; NOFO open through 6/17/26
		COMMUNICATION DISORDERS (4)		
52.	Advancement and Innovation in Measurement of Language Development and Predictors (R01/R21 Clinical Trial Not Allowed) (NIH/NICHD/NIDCD) PAR-25-112 (R01) PAR-25-113 (R21)	These NOFOs encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of children's language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable tools to further our understanding of children's language development and/or impairment, and predictors thereof. https://grants.nih.gov/grants/guide/pa-files/PAR-25-112.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-113.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 7/5/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COMMUNICATION DISORDERS		
53.	Information and Practice Needs Relevant to; and Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed) (NIH) PAR-25-217 PAR-25-220	These NOFOs support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to better understand the information and practice needs of caregivers, professionals, and other invested parties who support late talking children and to determine whether those needs are being effectively met; and that aim to further understanding of the developmental trajectories of late talking children by leveraging existing data and creating open and shared data resources to aid in identifying patterns and predictors of developmental outcomes in late talking children, and exploring potential underlying mechanisms, risk factors, and sequelae. https://grants.nih.gov/grants/guide/pa-files/PAR-25-217.html https://grants.nih.gov/grants/guide/pa-files/PAR-25-220.html	Up to $275,000, for up to 2 years	Multiple deadlines; NOFOs open through 10/2/25
		COMPLEMENTARY AND INTEGRATIVE HEALTH (6)		
54.	NCCIH Clinical Trials: Feasibility and Multi-Site Feasibility of Mind and Body Interventions; and Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01/R34 Clinical Trial Required) (NIH/NCCIH) PAR-25-267 (R01) PAR-25-268 (R01) PAR-25-274 (R34)	These NOFOs support feasibility and clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs in NCCIH-designated areas of high research priority. https://grants.nih.gov/grants/guide/pa-files/PAR-25-267.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-268.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-274.html (R34)	Dependent upon proposal, for up to 5 years (R01) Up to $450,000, for up to 3 years (R34)	Multiple deadlines; NOFOs open through 11/17/26
55.	NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award, Early Phase Clinical Trial Award, and Mid Phase Clinical Trial Award (R61/R33/R01 Clinical Trial Required) (NIH/NCCIH) PAR-25-269 (R61/R33) PAR-25-270 (R33) PAR-25-271 (R01)	These NOFOs encourage applications for investigator-initiated, early- and mid-phase, clinical trials of natural products, which have a strong scientific premise to justify further clinical testing. For these NOFOs, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound and have compelling preliminary evidence. https://grants.nih.gov/grants/guide/pa-files/PAR-25-269.html (R61/R33) https://grants.nih.gov/grants/guide/pa-files/PAR-25-270.html (R33) https://grants.nih.gov/grants/guide/pa-files/PAR-25-271.html (R01)	Up to $350,000 per year, for up to 5 years (R61/R33) Up to $350,000 per year, for up to 3 years (R01/R33)	Multiple deadlines; NOFOs open through 11/13/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DENTAL AND CRANIOFACIAL RESEARCH (3)		
56.	NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed) (NIH/NIDCR) PAR-25-105	This NOFO supports basic and clinical research, behavioral, and population science conducted by scientists who are establishing an independent research career in dental, oral and craniofacial research. https://grants.nih.gov/grants/guide/pa-files/PAR-25-105.html	Up to $100,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 1/7/28
57.	NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation (UG3/UH3 Clinical Trial Required) (NIH/NIDCR) PAR-25-188	This NOFO supports the planning and implementation of well-designed, rigorously conducted, behavioral/biopsychosocial intervention studies relevant to dental, oral, and craniofacial health as well as associated medical and mental health status or comorbidities. https://grants.nih.gov/grants/guide/pa-files/PAR-25-188.html	Dependent upon proposal, for up to 6 years	Multiple deadlines; NOFO open through 11/8/27
58.	NIDCR Prospective Observational or Biomarker Validation Study (U01 Clinical Trial Not Allowed) (NIH/NIDCR) PAR-25-239	This NOFO will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens. https://grants.nih.gov/grants/guide/pa-files/PAR-25-239.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 5/7/26
		DIGITAL HEALTHCARE (1)		
59.	Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional) (NIH/NINDS/NCI) PAR-25-170	This NOFO supports rigorous development and validation of DHT derived biomarkers or COAs for remote monitoring to fill a defined unmet clinical endpoint for interventional clinical trials. To increase standardization and improve clinical adoption, applicants must propose to develop and evaluate the DHT enabled biomarkers or COAs in three or more diseases or conditions. https://grants.nih.gov/grants/guide/pa-files/PAR-25-170.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 6/22/26
		DOWN SYNDROME (1)		
60.	Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trial Not Allowed) (NIH) PAR-25-214	The animal models and related biological materials developed must have utility in targeted or basic science studies in areas highly relevant to DS. The INCLUDE Project encourages projects focusing on development of various animal models, genetic resources, atlases at a single cell or subcellular level, advanced informatics technologies including AI/ML, and integration of multiple animal models and technology platforms for enhancing rigor and reproducibility of preclinical DS research. https://grants.nih.gov/grants/guide/pa-files/PAR-25-214.html	Up to $275,000, for up to 2 years	Multiple deadlines; NOFO open through 11/16/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE & METABOLIC DISEASE (2)		
61.	Forecast: Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed) (NIH/NIDDK) NOT-DK-24-032	This NOFO will solicit applications for a Hematology Coordinating Center (HCC) for the NIDDK Cooperative Centers of Excellence in Hematology (CCEH) Program. The HCC is expected to work collaboratively with up to 5 CCEHs as part of the NIDDK CCEH Program, which serves as a national resource for the larger nonmalignant hematology research community. https://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-032.html	$1 million	Estimated post date: 12/2/24 Estimated proposal date: 3/18/25
62.	NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional) (NIH/NIDDK) RFA-DK-26-001	This NOFO invites applications that propose CDTR to support research across the translational science spectrum. The purpose of this Centers program is to accelerate innovation of diabetes translation to maximize positive impacts of research on population health through activities and core services that offer specialized expertise, tools, education, and support. An emphasis on novel methods and research to address health equity and reduce diabetes-related health disparities is encouraged. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-001.html	Up to $400,000 per year, for up to 5 years	Letter of intent: 5/12/25 Proposal: 6/10/25
		ENVIRONMENTAL HEALTH (3)		
63.	Epitranscriptomics Crosstalks and Toxicants (EPCOT) (R01 Clinical Trials Not Allowed) (NIH/NIEHS) RFA-ES-25-001	This NOFO supports innovative studies to explore how exposures to environmental toxicants may inhibit, create new or otherwise impact epitranscriptomic crosstalks and provide mechanistic insights into how these interactions play a role in initiation, progression, and/or exacerbation of adverse health outcomes. https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-25-001.html	Up to $500,000, for up to 5 years	Letter of intent: 1/6/25 Proposal: 2/6/25
64.	Environmental Health Sciences Core Centers Program (P30 Clinical Trials Optional) (NIH/NIEHS) RFA-ES-25-002	The overall goal of an EHSCC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among environmental exposures, human biology, and disease. The EHSCC supports community engagement and translational research as key approaches to improving public health. https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-25-002.html	Up to $850,000 per year, for up to 4 years	Multiple deadlines; NOFO open through 1/29/27
65.	Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trials Not Allowed) (NIH/NIEHS) RFA-ES-25-003	This NOFO is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the NOFO is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-25-003.html	Up to $275,000, for up to 2 years	Multiple deadlines; NOFO open through 12/1/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		EPILEPSY (1)		
66.	Forecast: FY25 Epilepsy Research Program (ERP) (DoD/CDMRP)	Four awards are anticipated in the FY25 ERP: Idea Development Award; Leveraging Research Award; Research Partnership Award; and Virtual Post-Traumatic Epilepsy Research Faculty Award. All applications must address one or more of the Focus Areas: Markers and Mechanisms; Epidemiology; Longitudinal Studies; and Innovative Research. https://cdmrp.health.mil/pubs/press/2025/25erppreann	Up to $1.2 million, for up to 3 years Dependent upon award mechanism	TBD
		GENOMICS (11)		
67.	Rapid Inhibitor Discovery and Development pipeLine (RIDDL) (DoD/DARPA) DARPA-PS-25-03	The RIDDL program explicitly seeks transformative approaches that enable the rapid discovery, design, and development of novel inhibitors of gene editing technologies with enhanced activity, specificity, utility, and potency. These approaches could serve as a rapid response to the accidental or intentional misuse of gene editing technologies. https://sam.gov/opp/d04ec5d6949b435083f6f582300aca27/view	Dependent upon proposal and award mechanism	Proposal: 12/20/24
68.	NOSI: Somatic Cell Gene Editing Therapies to Improve Transplantation Outcomes (NIH/NIAID/NIDDK) NOT-AI-24-085	This NOSI supports research that applies somatic cell gene editing (SCGE) approaches in animal models or human tissues or organs excluded from clinical use to improve graft survival and outcomes for recipients of allogenic or xenogeneic solid organ or pancreatic islet transplants, or vascularized composite allografts (VCA). https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-085.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/16/27
69.	NIDCR Research Grants for Analyses of Existing Genomics Data (R01/R03 Clinical Trial Not Allowed) (NIH/NIDCR) PAR-25-164 (R01) PAR-25-166 (R03)	These NOFOs support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s). https://grants.nih.gov/grants/guide/pa-files/PAR-25-164.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-166.html (R03)	Dependent upon proposal, for up to 3 years (R01) Up to $100,000 per year, for up to 2 years (R03)	Multiple deadlines; NOFOs open through 5/7/26
70.	Investigator Initiated Innovation in Computational Genomics and Data Science (R01/R21 Clinical Trial Not Allowed) (NIH/NHGRI/NLM) PAR-25-228 (R01) PAR-25-229 (R21)	These NOFOs support investigator-initiated research efforts fostering innovation in computational genomics, data science, statistics, bioinformatics, and data visualization and exploration. They support development of innovative analytical methodologies and approaches and early-stage tools and software for genomics, rather than incremental advances or modification and application of existing approaches. https://grants.nih.gov/grants/guide/pa-files/PAR-25-228.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-229.html (R21)	Up to $500,000 per year, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 7/16/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS		
71.	Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01/R21 Clinical Trial Not Allowed) (NIH/NHGRI/NIMH/NCI) PAR-25-255 (R01) PAR-25-256 (R21)	These NOFOs support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets. https://grants.nih.gov/grants/guide/pa-files/PAR-25-255.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-256.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 11/16/26
72.	Advancing Genomic Medicine Research (R01/R21 Clinical Trial Optional/R03 Clinical Trial Not Allowed) (NIH/NHGRI) RFA-HG-25-002 (R01) RFA-HG-25-003 (R21) RFA-HG-25-004 (R03)	These NOFOs solicit proposals that stimulate innovation and advance understanding of when, where, and how best to implement the use and sharing of genomic information and technologies in clinical care provided to all persons irrespective of racial/ethnic background or socioeconomic status. https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-25-002.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-25-003.html (R21) https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-25-004.html (R03)	Dependent upon proposal, for up to 5 years (R01) Up to $250,000 per year, for up to 3 years (R21) Up to $50,000 per year, for up to 2 years (R21)	Proposal: 2/11/25
		HEALTH IT & DATA (10)		
73.	NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed) (NIH/NIDCR) PAR-25-045	This NOFO supports meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or that develop needed statistical methodology for analyzing existing dental, oral or craniofacial databases. https://grants.nih.gov/grants/guide/pa-files/PAR-25-045.html	Up to $100,000 per year, for up to 2 years	Proposal: 2/16/25
74.	Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed) (NIH/NICHD) PAR-25-092	This NOFO supports the archiving and documentation of existing data sets within the scientific mission of the NICHD in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding. https://grants.nih.gov/grants/guide/pa-files/PAR-25-092.html	Up to $50,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 11/16/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA		
75.	Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed) (NIH) PAR-25-109	This NOFO is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed. https://grants.nih.gov/grants/guide/pa-files/PAR-25-109.html	Up to $100,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 11/16/25
76.	NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) (NIH/NLM/ODSS) PAR-25-238	This NOFO focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects. https://grants.nih.gov/grants/guide/pa-files/PAR-25-238.html	Up to $250,000 per year, for up to 4 years	Multiple deadlines; NOFO open through 1/7/26
77.	Small Business Informatics Tools for the Pangenome (R43/R41 Clinical Trial Not Allowed) (NIH/NHGRI) PAR-25-308 (R43) PAR-25-309 (R41)	These NOFOs will support the development of informatics tools with commercial potential to facilitate uptake and scientific use of the human pangenome reference whose development is supported by the NHGRI Human Genome Reference Program (HGRP). https://grants.nih.gov/grants/guide/pa-files/PAR-25-308.html (R43) https://grants.nih.gov/grants/guide/pa-files/PAR-25-309.html (R41)	Up to $400,000 per year, for up to 1 year	Letter of intent: 2/3/25 Proposal: 3/3/25
78.	Accelerating the Pace of Substance Use Research Using Existing Data (R01/R21 Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-26-055 (R01) RFA-DA-26-056 (R21)	These NOFOs invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors and related disorders, prevention of substance use and HIV, and health service utilization. This NOFO encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-055.html https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-056.html	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 12/3/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA		
79.	Enhancing Reuse of NHGRI Data Assets (R03 Clinical Trial Not Allowed) (NIH/NHGRI) RFA-HG-25-005	The purpose of this concept is to encourage the genomics research community to leverage data sets available through NHGRI's AnVIL platform for innovative research and secondary analysis projects. https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-25-005.html	Up to $125,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 2/13/26
80.	Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed) (NIH/NHGRI/NIA/NCI) RFA-HG-25-007	This NOFO seeks applications for the development of informatics tools to facilitate uptake and scientific use of the human pangenome reference being developed and maintained by the NHGRI Human Genome Reference Program (HGRP). Emphasis for this RFA will be on development of tools to advance compelling use cases that are relevant to different broad sectors of the genomics community, e.g., clinical, population, or functional genomics. https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-25-007.html	Up to $400,000 per year, for up to 3 years	Letter of intent: 2/3/25 Proposal: 3/3/25
		HIV/AIDS (13)		
81.	Forecast: NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities (R34/R01) (NIH/NIDA) NOT-DA-24-051 (R34) NOT-DA-24-052 (R01)	The purpose of these initiatives is to stimulate observational or intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-051.html (R34) https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-052.html (R01)	TBD	Estimated post date: 6/2/25 Estimated proposal date: 12/15/25
82.	Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed) (NIH/ORIP/NIMH) PAR-25-165	This NOFO supports preclinical HIV/AIDS research using NHP models performed by Early Stage Investigators (ESIs) who are within 10 years of their terminal degree or completion of their residency training but who have at least two years of postdoctoral experience. https://grants.nih.gov/grants/guide/pa-files/PAR-25-165.html	Up to $275,000, for up to 2 years	Multiple deadlines; NOFO open through 9/7/25
83.	NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) (NIH/NIDA) PAR-25-261	This NOFO supports exceptionally creative scientists who propose high-impact studies that open new areas of HIV research in the context of SUD and/or lead to new avenues for prevention and treatment of HIV in people with SUD. The term "avant-garde" refers to highly innovative ideas and/or approaches that have the potential to be transformative. https://grants.nih.gov/grants/guide/pa-files/PAR-25-261.html	Up to $700,000 per year, for up to 5 years	Letter of intent: 7/15/25 Proposal: 8/15/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
84.	Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed) (NIH/NIAID) PAR-25-300	This NOFO supports the investigation of HIV-1 Envelope (Env) cell surface expression, the structural mechanism of biologic-mediated cell killing, and the development of novel approaches to enhance the recognition and elimination of Env-expressing, HIV-1 infected cells. https://grants.nih.gov/grants/guide/pa-files/PAR-25-300.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 1/7/28
85.	Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed) (NIH) PAR-25-330	This NOFO supports research to define the impact of defective HIV proviruses on mechanisms of HIV persistence and pathogenesis during antiretroviral treatment and their potential deleterious effects on HIV cure strategies and interference with HIV-specific molecular assays. https://grants.nih.gov/grants/guide/pa-files/PAR-25-330.html	Up to $500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 1/7/28
86.	HIV Prevention and Alcohol (R34/R01 Clinical Trials Optional) (NIH/NIAAA/ODP) PAS-25-161 (R34) PAS-25-208 (R01)	These NOFOs seek to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. https://grants.nih.gov/grants/guide/pa-files/PAS-25-161.html (R34) https://grants.nih.gov/grants/guide/pa-files/PAS-25-208.html (R01)	Up to $450,000, for up to 3 years (R34) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOFOs open through 5/7/26
87.	Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-24-076	This NOFO supports preclinical activities for the development of safe and effective long-acting/sustained release (LA/SR) technologies for prevention and treatment of HIV and HIV-associated tuberculosis (TB), hepatitis B (HBV) and hepatitis C (HCV), and to ultimately advance these products toward submission of an IND application. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-076.html	Up to $700,000 per year, for up to 3 years (R61) Up to $1 million per year, for up to 3 years (R33)	Letter of intent: 2/11/25 Proposal: 3/13/25
88.	Research to Address Systemic and Structural Barriers and Facilitators to Improve the HIV PrEP Care Continuum for People Who Use Substances (R01/R34 Clinical Trials Required) (NIH) RFA-DA-26-003 (R01) RFA-DA-26-004 (R34)	Research projects supported by these NOFOs will develop, implement, and evaluate system/structural-directed strategies that meet the needs of people who use substances to improve the PrEP uptake and persistence. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-003.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-004.html (R34)	Up to $500,000 per year, for up to 5 years (R01) Up to $450,000, for up to 3 years (R34)	Letter of intent: 2/12/25 Proposal: 3/12/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
89.	Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01/R21 Clinical Trial Not Allowed) (NIH/NIMH/NIDA/NINDS) RFA-MH-26-110 (R01) RFA-MH-26-111 (R21)	These NOFOs encourage research to define the mechanisms and roles of T-cells in HIV/CNS reservoir seeding, persistence and neuropathogenesis. Strategies to develop therapeutic approaches to target T-cell neuro-invasion, reservoir maintenance, and neuropathogenesis is also an area of high priority. State-of-the-art CNS cell systems, organoid models, post-mortem tissue, animal models, clinical samples and single-cell technologies can be used as potential tools to address this research area. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-26-110.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-26-111.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Letter of intent: 2/18/25 Proposal: 3/18/25
		IMMUNOLOGY & INFECTIOUS DISEASE (7)		
90.	2026 NIAID DMID Omnibus Broad Agency Announcement (NIH/NIAID) HHS-NIH-NIAID-BAA2025-1	This BAA is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for biodefense and emerging infectious diseases. Research areas include: Development of Candidate Therapeutics, Vaccines, and In Vitro Diagnostics for Antimicrobial-Resistant (AMR) Bacterial or Fungal Pathogens; and Development of Direct Acting Antivirals (DAA) for Viral Families of Pandemic Potential. https://sam.gov/opp/e1e43a392c2449e6805b9300906222a2/view	Dependent upon topic area	Proposal: 1/21/25
91.	NOSI: Accelerating Malaria Vaccine and Monoclonal Antibody Discovery (NIH/NIAID) NOT-AI-24-072	This NOSI invites applications proposing early-phase translational research to generate new malaria vaccine candidates or monoclonal antibody (mAb)-based interventions suitable for further downstream development and clinical evaluation, particularly for *Plasmodium falciparum* and *P. vivax*. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-072.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/16/27
92.	NOSI: Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity (NIH/NIAID) NOT-AI-24-078	This NOSI solicits research on the immunologic characterization of mice with diverse microbial experience to determine their usefulness as research tools for advancing understanding of human immune status and function during homeostasis or in infectious or immune-mediated diseases. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-078.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/16/27
93.	NOSI: Advancing Research Needed to Develop a Universal Influenza Vaccine (NIH/NIAID) NOT-AI-24-081	The proposed research should have clear relevance to three major research areas: Improve understanding of transmission, natural history and pathogenesis of influenza virus infection; Characterize influenza immunity and correlates of immune protection; Support rational design of universal influenza vaccines. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-081.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/16/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MATERNAL AND PEDIATRIC HEALTH (8)		
94.	Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01/R21 Clinical Trial Optional) (NIH) PAR-25-110 (R01) PAR-25-111 (R21)	These NOFOs support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. https://grants.nih.gov/grants/guide/pa-files/PAR-25-110.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-111.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 3/16/26
95.	NICHD Small Research Grant Program (R03 Clinical Trial Required/R03 Basic Experimental Studies with Humans Required) (NIH/NICHD) PAR-25-125 PAR-25-126	The NICHD supports research in areas relevant to human development, including: contraception, fertilization, pregnancy, childbirth, prenatal and postnatal development; childhood development through adolescence; intellectual and developmental disabilities; and rehabilitation medicine. These NOFOs are specifically for receipt of applications within the NICHD mission that propose one or more clinical trials. https://grants.nih.gov/grants/guide/pa-files/PA-25-125.html https://grants.nih.gov/grants/guide/pa-files/PA-25-126.html	Up to $50,000 per year, for up to 2 years	Multiple deadlines; NOFOs open through 1/7/28
96.	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33/R34 Clinical Trial Optional) (NIH/NIAAA) PAR-25-158 (R61/R33) PAR-25-159 (R34)	These NOFOs focus on prevention and intervention strategies for FASD throughout the lifespan. They support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. https://grants.nih.gov/grants/guide/pa-files/PAR-25-158.html (R61/R33) https://grants.nih.gov/grants/guide/pa-files/PAR-25-159.html (R34)	Up to $350,000, for up to 2 years (R61) Up to $500,000 per year, for up to 3 years (R33) Up to $450,000, for up to 3 years (R34)	Multiple deadlines; NOFOs open through 11/16/27
97.	Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01/R21 - Clinical Trial Optional) (NIH/NICHD) PAR-25-265 (R01) PAR-25-266 (R21)	These NOFOs encourage research relevant to the development of novel screening approaches and/or therapeutic interventions for conditions for which newborn screening has already been implemented, as well as for potentially fatal or disabling genetic conditions that could benefit in the near future from the early detection made possible by newborn screening. https://grants.nih.gov/grants/guide/pa-files/PAR-25-265.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-266.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 11/16/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL COUNTERMEASURES (2)		
98.	Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 CT Not Allowed) (NIH/NIDA/NIAID) RFA-DA-26-034	This NOFO will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids and their combinations. This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-034.html	Up to $300,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 11/18/27
99.	Planning Announcement: Generally Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and industry partners (DoD/Army) W911SR-25-S-GUIDE	GUIDE impacts the discovery and design of biological products (e.g., monoclonal antibodies and vaccines) as well as small molecule drugs by simultaneously optimizing critical quality attributes of safety, efficacy, manufacturability and pharmacokinetics/pharmacodynamics while concurrently accounting for critical design attributes affecting developability and biophysical properties. https://sam.gov/opp/3682a79a97e34c87a3f3a589524aaeaa/view	TBD	Proposal: 10/18/28
		MENTAL HEALTH (20)		
100.	Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional); and Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) (NIH/NIMH) PAR-25-034 (UG3/UH3) PAR-25-035 (R01)	These NOFOs support efforts to optimize and evaluate: measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses; and pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. https://grants.nih.gov/grants/guide/pa-files/PAR-25-034.html (UG3/UH3) https://grants.nih.gov/grants/guide/pa-files/PAR-25-035.html (R01)	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFOs open through 6/20/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH		
101.	Schizophrenia and related disorders during mid- to late-life (R01/R21 Clinical Trial Optional) (NIH/NIMH) PAR-25-039 (R01) PAR-25-040 (R21)	These NOFOs encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. https://grants.nih.gov/grants/guide/pa-files/PAR-25-039.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-040.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 7/16/27
102.	Social disconnection and Suicide Risk in Late Life (R21/R01 Clinical Trial Optional) (NIH/NIMH) PAR-25-066 (R21) PAR-25-067 (R01)	These NOFOs encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. https://grants.nih.gov/grants/guide/pa-files/PAR-25-066.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-25-067.html (R01)	Up to $275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOFOs open through 7/16/26
103.	Full-Scale and Pilot Hybrid Effectiveness-Implementation Trials; and Effectiveness Trials for Mental Health Interventions (R01/R61/R33 - Clinical Trial Required) (NIH/NIMH) PAR-25-177 (R01) PAR-25-178 (R01) PAR-25-285 (R61/R33)	These NOFOs support clinical trials that are consistent with NIMH's priorities for: 1) optimizing preventive and therapeutic interventions with previously demonstrated efficacy for use with broader target populations or for delivery routine care, school, community, or online settings, and 2) research on implementation strategies that support the delivery and sustainability of optimized interventions in accessible settings. https://grants.nih.gov/grants/guide/pa-files/PAR-25-177.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-178.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-285.html (R61/R33)	Dependent upon proposal, for up to 5 years (Full R01) Up to $250,000 per year, for up to 3 years (Pilot R01) Dependent upon proposal, for up to 5 years (R61/R33)	Multiple deadlines; NOFO open through 10/15/27
104.	Confirmatory Efficacy Clinical Trials of Non-Pharmacological and Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) (NIH/NIMH) PAR-25-179	The purpose of this NOFO is to support confirmatory efficacy testing of non-pharmacological preventive and therapeutic interventions, and under certain conditions, selected pharmacological interventions for mental disorders in adults and children through an experimental therapeutics approach. https://grants.nih.gov/grants/guide/pa-files/PAR-25-179.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 10/15/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH		
105.	First in Human and Early Stage Testing of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01/R61/R33 Clinical Trial Required) (NIH/NIMH) PAR-25-180 (U01) PAR-25-183 (R33) PAR-25-184 (R61/R33)	These NOFOs support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices; and early-stage testing of pharmacologic interventions with novel mechanisms of action or neuromodulatory device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness. https://grants.nih.gov/grants/guide/pa-files/PAR-25-180.html (U01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-183.html (R33) https://grants.nih.gov/grants/guide/pa-files/PAR-25-184.html (R61/R33)	Dependent upon proposal, for up to 5 years (U01/R61/R33) Dependent upon proposal, for up to 3 years (R61/R33)	Multiple deadlines; NOFO open through 10/15/27
106.	Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) (NIH/NIMH) PAR-25-181 (R33) PAR-25-182 (R61/R33)	These NOFOs encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. They are intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. https://grants.nih.gov/grants/guide/pa-files/PAR-25-181.html (R33) https://grants.nih.gov/grants/guide/pa-files/PAR-25-182.html (R61/R33)	Dependent upon proposal, for up to 3 years (R33) Dependent upon proposal, for up to 5 years (R61/R33)	Multiple deadlines; NOFO open through 10/15/27
107.	Neuromodulation/ Neurostimulation Device Development for Mental Health Applications (R21/R01 Clinical Trial Not Allowed) (NIH/NIMH) PAR-25-286 (R21) PAR-25-287 (R01)	These NOFOs encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared. https://grants.nih.gov/grants/guide/pa-files/PAR-25-286.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-25-287.html (R01)	Up to $275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOFOs open through 11/16/27
108.	Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01/R21 CT Optional) (NIH/NIMH) PAR-25-290 (R01) PAR-25-291 (R21)	These NOFOs encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. They aim to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. https://grants.nih.gov/grants/guide/pa-files/PAR-25-290.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-291.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 11/16/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH		
109.	Improving Mental and Behavioral Health Topical PCORI Funding Announcement -- Cycle 1 2025 (PCORI)	This opportunity aims to fund studies comparing two or more approaches for prevention, diagnosis, treatment or care delivery related to mental and behavioral health conditions. Studies should address a critical clinical or care delivery problem. SAEs include: Mental and behavioral health of children and youth; Suicide prevention and crisis response; Strategies to improve mental health care access and delivery. https://www.pcori.org/funding-opportunities/announcement/improving-mental-and-behavioral-health-topical-pcori-funding-announcement-cycle-1-2025	Up to $12 million, for up to 5 years	Letter of intent: 1/14/25 Proposal: 5/6/25
		MUSCULOSKELETAL HEALTH (6)		
110.	Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required) (NIH/NIAMS) PAR-24-279	This NOFO is designed to facilitate clinical trials that can be completed within a limited time frame. The trials must address research questions related to the mission and goals of the NIAMS and may evaluate interventions with drugs, biologics, devices, or surgical, dietary, behavioral or rehabilitation therapies. https://grants.nih.gov/grants/guide/pa-files/PAR-24-279.html	Up to $600,000, for up to 3 years	Multiple deadlines; NOFO open through 11/2/26
111.	Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) (NIH/NIAMS) PAR-24-280	This NOFO encourages applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. https://grants.nih.gov/grants/guide/pa-files/PAR-24-280.html	Up to $475,000, for up to 4 years	Multiple deadlines; NOFO open through 11/2/26
112.	Ancillary Studies to Ongoing Clinical Projects (R01/R21 Clinical Trial Not Allowed) (NIH/NIAMS) PAR-24-289 (R01) PAR-25-230 (R21)	These NOFOs solicit applications that propose to conduct time-sensitive ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, active, ongoing clinical projects. The parent project can be an interventional clinical trial, or a clinical study. https://grants.nih.gov/grants/guide/pa-files/PAR-24-289.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-230.html (R21)	Up to $300,000 per year, for up to 4 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 12/5/25
113.	NCMRR Early Career Research Award (R03 Clinical Trial Optional) (NIH/NICHD) PAR-25-124	The research must be focused on one or more of the areas within the biomedical and behavioral mission of NCMRR, which include: pathophysiology and management of chronically injured nervous and musculoskeletal systems; rehabilitative strategies involving pharmaceutical, stimulation, and neuroengineering approaches, exercise, and behavioral modifications. https://grants.nih.gov/grants/guide/pa-files/PAR-25-124.html	Up to $100,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 11/16/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MUSCULOSKELETAL HEALTH		
114.	NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) (NIH/NIAMS) PAR-25-141	This NOFO solicits applications for implementation of investigator-initiated, single or multi-site, interventional clinical trials. NIAMS expects trials to be hypothesis-driven and have the potential for high clinical impact within the research mission of NIAMS. https://grants.nih.gov/grants/guide/pa-files/PAR-25-141.html	Up to $250,000, for up to one year (UG3) Dependent upon proposal, for up to 5 years (UH3)	Multiple deadlines; NOFO open through 3/4/27
		RARE DISEASES (1)		
115.	Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) (NIH/NCATS) RFA-TR-25-002	This NOFO provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-25-002.html	Up to $275,000, for up to 2 years	Multiple deadlines; NOFO open through 6/2/26
		REPRODUCTIVE HEALTH (1)		
116.	Contraceptive Development Research Centers (P50 Clinical Trial Optional) (NIH/NICHD) RFA-HD-26-004	This NOFO supports and facilitates multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Development Research Center. This NOFO also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success. https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-26-004.html	Up to $1.3 million per year, for up to 4 years	Letter of intent: 10/12/25 Proposal: 11/12/25
		SLEEP HEALTH (1)		
117.	Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional) (NIH) PAR-24-330	The purpose of this initiative is to support non-pharmacological interventions to promote sleep health, reduce sleep health disparities, and examine sleep as a modifiable factor to reduce disparities for other health outcomes among populations that experience health disparities. https://grants.nih.gov/grants/guide/pa-files/PAR-24-330.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 7/5/27
		SMALL BUSINESS DEVELOPMENT (4)		
118.	Forecast: NASA SBIR and STTR Phase I Research Topics (NASA) 80NSSC25Ph1SBIRSN1 80NSSC25STTRSN1	Topics include: Oxygen Compatible Habitation Solutions for Exploration Environments; Long-Duration Exploration PLSS Capabilities; In Situ Sample Preparation and Analysis for Biological and Physical Sciences in a Microgravity Environment; and Biomanufacturing for Space Missions: Harnessing Microbial Communities for Sustainable Production in Moon and Mars Environments. https://sam.gov/opp/be2eac58dd024c5bb4874015e71846b1/view https://sam.gov/opp/d5acc6a544a047c9a67b0cea7501153d/view	Up to $150,000	Post date: 1/7/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT		
119.	DHA 2025.1 SBIR and STTR (DoD/DHA) DoD SBIR 2025.1 DoD STTR 2025.A	Topics in this SBIR and STTR release include: Platelet Contractility / Retraction Measurement Device; A Mobile Application for Prediction of Blast Overpressure Exposure in Civilian and Military Operations; and Development of Organoid Screening Tool for High-Throughput Compound Screening to Be Used in Military-Relevant Exposures. https://www.dodsbirsttr.mil/topics-app/	Up to $250,000, for 6 months (Phase I) Up to $1.3 million, for up to 2 years (Phase II)	Proposal: 2/5/25
120.	Forecast: FY 2025 Phase I Release 2 (DoE)	Topics of this DoE SBIR/STTR release are anticipated to include: Plastic Circularity and Bioenergy Feedstock Logistics Improvements. https://science.osti.gov/-/media/sbir/pdf/funding/2025/2025-Phase-I-Release-2-Topics-V3-11-13-2024.pdf	Up to $250,000, for up to 1 year (Phase I) Up to $1.6 million (Phase II)	Post date: 12/16/24 Letter of intent: 1/7/25 Proposal: 2/26/25
		SOCIAL DETERMINANTS OF HEALTH (3)		
121.	Forecast: NINR Areas of Emphasis for Research to Optimize Health for All (R01/R21 Clinical Trial Optional) (NIH/NINR) NOT-NR-25-006 (R01) NOT-NR-25-007 (R21)	These NOFOs will solicit applications that propose independent research projects that are consistent with the scientific framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. Research projects should be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy. https://grants.nih.gov/grants/guide/notice-files/NOT-NR-25-006.html (R01) https://grants.nih.gov/grants/guide/notice-files/NOT-NR-25-007.html (R21)	TBD	Estimated post date: 1/5/28 Estimated proposal date: 2/5/25
122.	The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional) (NIH) PAR-25-292	This NOFO supports innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities. https://grants.nih.gov/grants/guide/pa-files/PAR-25-292.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 1/7/28
		SUBSTANCE USE DISORDER (17)		
123.	NOSI: Discovery and Development of Natural Products to Treat Substance Use Disorders (SUDs) (NIH/NIDA/NCCIH) NOT-DA-25-032	This NOSI highlights interest in receiving grant applications for innovative NP-focused research involving lead discovery and drug development to address the challenges of SUDs. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-25-032.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
124.	Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01R34 Clinical Trial required) (NIH/NIAAA) PA-25-163 (R01) PAR-25-193 (R34)	These NOFOs will focus broadly on topics relevant for treatment of and recovery from AUD, including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery. https://grants.nih.gov/grants/guide/pa-files/PA-25-163.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-193.html (R34)	Up to $500,000 per year, for up to 5 years (R01) Up to $450,000, for up to 3 years (R34)	Multiple deadlines; NOFOs open through 7/16/26
125.	Alcohol Health Services Research (R01/R34 Clinical Trial Optional) (NIH/NIAAA) PA-25-245 (R01) PAR-25-192 (R34)	These NOFOs will broadly focus on closing the treatment gap for individuals with AUD; within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations. https://grants.nih.gov/grants/guide/pa-files/PA-25-245.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-192.html (R34)	Up to $500,000 per year, for up to 5 years (R01) Up to $450,000, for up to 3 years (R34)	Multiple deadlines; NOFOs open through 7/16/26
126.	Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional) (NIH/NIDA) PAR-25-100	This NOFO encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of tobacco or substance use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. https://grants.nih.gov/grants/guide/pa-files/PAR-25-100.html	Up to $450,000, for up to 3 years	Multiple deadlines; NOFO open through 5/7/27
127.	Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R43/R41 - Clinical Trials Optional) (NIH/NIDA) RFA-DA-26-016 (R43) RFA-DA-26-017 (R41)	These NOFOs invite applications proposing research and development of medical devices specifically indicated for pediatric population affected by substance use and addiction. To enhance the likelihood of success, applicants are encouraged to include plans to address both the technical and the commercial feasibility of their idea, culminating in reaching specific milestones. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-016.html (R43) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-017.html (R41)	Up to $400,000, for up to 1 year	Letter of intent: 1/25/25 Proposal: 2/26/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
128.	Drug Repurposing and Repositioning Insights for Treating SUDs Challenge (NIH/NIDA)	The Challenge goal is to uncover novel insights for therapeutic approaches that can be rapidly translated into clinical practice, offering new hope for individuals struggling with SUD. NIDA invites academic researchers, addiction treatment providers, and biotech scientists to submit their pioneering ideas for repurposing or repositioning existing drugs to treat SUDs. https://www.challenge.gov/?challenge=nida-drug-repurposing-and-repositioning	Up to $10,000	Proposal: 1/8/25
		TELEMEDICINE (1)		
129.	Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional) (NIH) PAR-25-242	The purpose of this NOFO is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mHealth interventions or tools specifically suited for LMICs that utilize new or emerging technology, platforms, systems, and/or analytics. https://grants.nih.gov/grants/guide/pa-files/PAR-25-242.html	Up to $125,000 per year, for up to 2 years (R21) Up to $200,000 per year, for up to 3 years (R33)	Multiple deadlines; NOFO open through 3/20/26
		THERAPEUTICS (3)		
130.	NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required) (NIH/NINDS) PAR-25-054	The purpose of this NOFO is to encourage grant applications for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the NINDS. These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, and early studies of surgical, behavioral, or rehabilitation therapies. https://grants.nih.gov/grants/guide/pa-files/PAR-25-054.html	Dependent upon proposal, for up to 5 years	Letter of intent: 1/10/25 Proposal: 2/10/25
131.	NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional) (NIH/NINDS) PAR-25-133	This NOFO encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) or biomarker validation studies that may contribute to the justification for and provide the data required for designing future clinical studies. https://grants.nih.gov/grants/guide/pa-files/PAR-25-133.html	Up to $3 million per year, for up to 5 years	Multiple deadlines; NOFO open through 9/5/27
132.	Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) (NIH/NCATS) PAR-25-157	This program will support the early-stage proof of concept, high-risk and potentially high-reward studies for feasibility and exploratory technology development, which can transform or significantly improve the efficiency of therapeutic development to achieve NCATS ultimate goals - more treatments to all people more quickly. The research proposed should be for the development of technology that can break new ground or extend present technology toward new directions or novel applications. https://grants.nih.gov/grants/guide/pa-files/PAR-25-157.html	Up to $275,000, for up to 2 years	Proposal: 6/19/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		WOMEN'S HEALTH (2)		
133.	Mood and Psychosis Symptoms during the Menopause Transition (R01/R21 Clinical Trial Optional) (NIH/NIMH/ORWH) PAR-25-281 (R01) PAR-25-282 (R21)	These NOFOs encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption, emotion dysregulation, and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts. https://grants.nih.gov/grants/guide/pa-files/PAR-25-281.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-282.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 11/16/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
134.	Office-Wide Innovative Solutions Opening for Resilient Systems Office (RSO) ARPA-H-SOL-24-103	RSO seeks solution summaries and proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. The following interest areas categorize the ground-breaking research we seek to support: Sociotechnical System Innovation; Health Ecosystem Integration; and Adaptive & Antifragile Solutions. https://sam.gov/opp/76679cd8810f40229694c60c0a593302/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
135.	Office-Wide Innovative Solutions Opening for Health Science Futures (HSF) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/opp/9a301dc812ba47268323e3130e381f19/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
136.	Office-Wide Innovative Solutions Opening for Scalable Solutions Office (SSO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Scalable Technologies and Interventions; Collaborative Distribution Networks; and Biomanufacturing Innovations. https://sam.gov/opp/134cdc5d93b34c0ea39498055f315624/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
137.	Office-Wide Innovative Solutions Opening for Proactive Health Office (PHO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/opp/53707a1538994e7d9ed8df8e5ee95ed1/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (3)		
138.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/search-results-detail/327332	Up to $49 million, per award	White papers accepted on rolling basis until 5/1/25
139.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/search-results-detail/345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
140.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (9)		
141.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b253646698 57a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
142.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
143.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
144.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
145.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
146.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
147.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
148.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/search-results-detail/327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
149.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative CBRNE defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Advanced materials and manufacturing science. https://sam.gov/opp/6e54cc4efc0b4aae97ed39666a15b004/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29
		BARDA (2)		
150.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/764c53aa6dac43538ef902a2bc2af44f/view	Dependent upon proposal	Proposal: 9/25/28
151.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #15: ReDIRECT; AOI #19: Healing Lungs; AOI #22: ReBooT; AOI #28: Influenza Vaccine Innovation. https://sam.gov/opp/8f4d63db541c46ff9e339d8c43d0ad86/view	Up to $750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DARPA (2)		
152.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/5fff3c4c76c341a4a6b1d2010211c793/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/10/25
153.	Defense Sciences Office, Office-wide HR001124S0039	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. https://sam.gov/opp/3c1deaa286b74897bed07f3eefb446a0/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/25
		DEFENSE THREAT REDUCTION AGENCY (4)		
154.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E: • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
155.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
156.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8e0d71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY		
157.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to $1 million per year, for up to 5 years	White papers accepted through 9/2034
		DEPARTMENT OF ENERGY (1)		
158.	FY 2025 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003432	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature's mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/356590	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/25
		NATIONAL SCIENCE FOUNDATION (2)		
159.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 24-579	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View the full list of topics. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-0/nsf24-579/solicitation	Up to $275,000 for up to 1 year	Project pitches accepted on a rolling basis Proposal: 3/5/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION		
160.	NSF Small Business Innovation Research / Small Business Technology Transfer Fast-Track Pilot Programs (SBIR-STTR Fast-Track) NSF 24-582	The NSF SBIR/STTR Fast-Track programs provide non-dilutive, fixed amount cooperative agreements for the development of a broad range of technologies based on discoveries in science and engineering with the potential for societal and economic impacts. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-1/nsf24-582/solicitation	Up to $1,555,000, for up to 3 years	Project pitches accepted on a rolling basis Proposal: 3/5/25
		NAVY (3)		
161.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.onr.navy.mil/work-with-us/funding-opportunities/fy25-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/25
162.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/1e5fbd8c66d949fdb4cfe0afc8b0b76b/view	Dependent upon proposal and award mechanism	White papers accepted through 12/31/24
163.	FY24 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943024S2000	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/2397c9059c3942cfb618400b2d8637e2/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/7/25
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
164.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH INSTITUTE (8)		
165.	Phased Large Awards for Comparative Effectiveness Research (PLACER) -- Cycle 1 2025	This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. Applications must address at least one of the National Priorities for Health. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-1-2025	Up to $22 million, for up to 6.5 years	Letter of intent: 1/14/25 Proposal: 5/6/25
166.	Broad Pragmatic Studies Funding Announcement -- 2024 Standing PFA -- Cycle 1 2025	This PFA invites applications for high-quality comparative clinical effectiveness research projects. All applications must align the proposed research with at least one of the National Priorities for Health. Applicants have the option to choose up to three of twelve topic themes, based on how their proposed research aligns with the themes. Cycle 3 SAEs include: Social Isolation and Loneliness in Older Adults, Health Communication Strategies for Uptake of COVID-19 Vaccine, and Promoting Sleep Health in Inpatient Settings. https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-1-2025	Up to $12 million, for up to 5 years Dependent upon award mechanism	Letter of intent: 1/14/25 Proposal: 5/6/25
167.	Advancing the Science of Engagement PCORI Funding Announcement -- Cycle 1 2025	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-1-2025	Up to $1.5 million, for up to 3 years	Letter of intent: 1/14/25 Proposal: 5/6/25
168.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research -- Cycle 1 2025	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-1-2025	Up to $750,000, for up to 3 years	Letter of intent: 1/14/25 Proposal: 5/6/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
169.	Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments -- Cycle 1 2025	For this PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI); Several kinds of therapy and medicines can reduce or stop symptoms for people with PTSD; The use of narrow-spectrum versus broad-spectrum antibiotics to treat children's acute respiratory tract infections (ARTIs). https://www.pcori.org/funding-opportunities/announcement/open-competition-implementation-findings-pcoris-research-investments-pcori-funding-announcement-cycle-1-2025	Up to $2.5 million, for up to 3 years	Letter of intent: 1/14/25 Proposal: 5/6/25
170.	Engagement Award: Capacity Building -- Spring 2025 Cycle	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-spring-2025-cycle	Up to $300,000, for up to 2 years	System opens: 1/16/25 Letter of intent: 4/1/25 Proposal: 7/10/25
171.	Engagement Award: Stakeholder Convening Support -- Spring 2025 Cycle	The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. https://www.pcori.org/funding-opportunities/announcement/engagement-award-convening-support-spring-2025-cycle	Up to $125,000, for up to 1 year	System opens: 1/16/25 Letter of intent: 4/1/25 Proposal: 7/10/25
172.	Engagement Award: Dissemination Initiative -- Spring 2025 Cycle	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-spring-2025-cycle	Up to $300,000, for up to 2 years	System opens: 1/16/25 Letter of intent: 4/1/25 Proposal: 7/10/25

GBG Acronyms

Updated Monthly

December 11, 2024

https://www.g2gconsulting.com/gbg-reporting-service/

Terms

AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

NIH Institutes and Centers

CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Back to Table of Contents